Table 1 |
||||||
|
Summary of additional medication, clinical and serologic characteristics of the analyzed lupus patients |
||||||
|
AZA |
MMF |
No IS |
||||
|
n = 30 |
% |
n = 39 |
% |
n = 38 |
% |
|
|
|
||||||
|
Medication a |
||||||
|
Prednisone |
26 |
87 |
38 |
97 |
14 |
37 |
|
mg/day, median (range) |
5.0 (0-50) §§§ |
5.0 (0-30)### |
0 (0-20)§§§ ### |
|||
|
Hydroxychloroquine |
17 |
57 |
26 |
67 |
29 |
76 |
|
Manifestations a |
||||||
|
Nephritis |
20 |
67 |
35 |
90 |
13 |
34 |
|
Proliferative class III, IV of all biopsy results available |
12 |
75 |
22 |
76 |
3 |
38 |
|
CRF grade III+ |
5 |
25 |
6 |
17 |
1 |
8 |
|
Nephritis in remission |
9 |
45 |
20 |
57 |
7 |
58 |
|
Active nephritis |
11 |
55 |
15 |
43 |
6 |
46 |
|
New nephritis |
1 |
5 |
0 |
0 |
6 |
46 |
|
Arthritis |
3 |
10 |
2 |
5 |
9 |
24 |
|
Serositis |
1 |
3 |
0 |
0 |
4 |
11 |
|
Myositis |
2 |
7 |
1 |
3 |
0 |
0 |
|
CNS |
1 |
3 |
0 |
0 |
1 |
3 |
|
Vasculitis |
1 |
3 |
1 |
3 |
1 |
3 |
|
Flaresa |
14 |
47 |
9 |
23 |
12 |
32 |
|
Lupus nephritis flare |
10 |
71 |
4 |
44 |
6 |
50 |
|
CNS flare |
0 |
0 |
0 |
0 |
1 |
3 |
|
Arthritis flare |
0 |
0 |
2 |
22 |
5 |
42 |
|
Serositis flare |
2 |
14 |
0 |
0 |
3 |
8 |
|
Myositis flare |
1 |
7 |
1 |
11 |
0 |
0 |
|
Vasculitis flare |
0 |
0 |
1 |
11 |
0 |
0 |
|
Ref. thrombocytopenia |
0 |
0 |
1 |
11 |
0 |
0 |
|
ILD flare |
1 |
7 |
0 |
0 |
0 |
0 |
|
Autoantibodies a |
||||||
|
Anti-dsDNA |
27 |
90 |
36 |
92 |
28 |
74 |
|
C median, U/ml (range) |
39 (0-1,250) |
29 (0-1,065) |
32 (0-1,496) |
|||
|
Anti-Ro |
17 |
57 |
16 |
41 |
24 |
65 |
|
Anti-La |
8 |
27 |
6 |
15 |
10 |
27 |
|
Anti-U1RNP |
11 |
37 |
14 |
36 |
20 |
54 |
|
Anti-SM |
6 |
20 |
6 |
15 |
8 |
22 |
|
APLA/LA |
10 |
33 |
14 |
38b |
9 |
28b |
|
Consumption of complement factors a |
15 |
50 |
16 |
41 |
15 |
39 |
|
SLEDAI |
||||||
|
Median (range) |
6 (0-18) |
4 (0-14) |
4 (0-24) |
|||
|
|
||||||
|
Results are presented as number and percent of patients unless otherwise stated. aResulting in an intensification of the immunosuppressive therapy (> 50mg prednisone-equivalent added, or switch of the therapy regimen to a more potent regimen, such as cyclophosphamide). AZA, azathioprine; MMF, mycophenolate mophetil; IS, immunosuppression; CRF, chronic renal failure; CNS, central nervous system; ILD, interstitial lung disease; APLA, anti-phospholipid antibodies; LA, lupus anticoagulant; SLEDAI, SLE disease activity index. bData incomplete (antibody status known in 37 and 32 patients respectively). Statistically significant differences detected between the dose of prednisone-equivalent, Dunn's Multiple Comparison test: #P < 0.05, ##P < 0.01, ###P < 0.001 statistically significant differences between patients taking MMF compared to patients without immunosuppressive therapy (no IS). §P < 0.05, §§P < 0.01, §§§P < 0.001 for statistically significant differences between patients taking AZA compared to patients without immunosuppressive therapy. |
||||||
|
Eickenberg et al. Arthritis Research & Therapy 2012 14:R110 doi:10.1186/ar3835 |
||||||
